Qiagen on Tuesday said that its variant interpretation and reporting software, Qiagen Clinical Insight (QCI) Interpret, is being deployed as a part of a national initiative in Denmark to offer sequencing for cancer patients.
The Danish National Genome Center selected QCI Interpret to provide interpretation of oncology results generated from whole-genome sequencing (WGS) data, Qiagen said.
The initiative is part of a larger personalized medicine strategy that aims to provide WGS as a standard-of-care for relevant patient groups throughout Denmark.
Qiagen noted that Denmark is one of the first countries in the world to implement WGS as standard-of-care for oncology at this scale.
“Denmark is taking a visionary approach to aggregating genomic data and combining it with clinical information on cancer patients to develop enhanced population-specific knowledge and reference sets for the country’s residents,” Jonathan Sheldon, executive vice president and head of Qiagen Digital Insights, said in a statement. “This will serve as a foundation for effective precision medicine capabilities for years to come.“
